Generated by AI
Cerus Corporation is a biomedical products company focused on blood transfusion safety. The company develops and commercializes the INTERCEPT Blood System, a pathogen-reduction platform designed to help safeguard donated blood components intended for transfusion. Its current product line includes systems for platelets and plasma, and it also supports blood centers, hospitals, and other healthcare institutions that rely on treated blood products. Cerus Corporation operates within the healthcare and medical technology markets, with its products used to reduce the risk of blood-borne pathogens while preserving the therapeutic value of transfused components. Headquartered in Concord, California, Cerus Corporation is dedicated to advancing technologies that support safer blood supply workflows across clinical settings.
Website1220 Concord Avenue
Concord, CA, 94520
United States
The latest articles about CERS.
A shift to higher-margin kit distribution and a successful red blood cell trial position Cerus for path to GAAP profitability.
Cerus Corp (CERS) reaffirmed full-year product revenue guidance of $229 million to $231 million while posting a GAAP net loss under $1 million and positive operating cash flow of $3 million.
Summary of Nov 3's posts. Generated by AI.
Summary of May 1's posts. Generated by AI.
Summary of Nov 2's posts. Generated by AI.
Investors talking about CERS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.